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Nature remains the main source of pharmacological molecules. Unfortunately, highly active is often linked to poor oral
bioavailability, mostly explained by low hydrosolubility. Thus, pharmacomodulation of natural scaffolds is often reported to
increase these properties. Ellagic acid (Fig. 1) is one of them: numerous biological effects (anticancer, antimicrobial,
antiplasmodial…) impede by a low water solubility (6 µg/mL), helped by inter-/intramolecular bonds and planar aspect of this
structure1. Different strategies could be employed to enhance solubility and by extension, improving PK/PD properties (Figure 2)².
Figure 1 : Ellagic acid (EA)
A total synthesis approach (Figure 3) was finally selected, based on EA’s
natural monomer, gallic acid and inspired by ellagitanins synthesis3.
Following this strategy, we expect to obtain (a)symetric compounds with
hydrophilic/alkyl chains to disrupt crystal packing, in addition to loss of
molecular planarity. The modifications have been performed on phenolic
functions (para) and several assays have been achieved to explore the
influence of these pharmacomodulations on critical parameters (Figure 4).Figure 2 : Critical properties
i CH3OH, H2SO4 ii Ac2O, H2SO4 iii BnBr, KI, K2CO3, DMK iv K2CO3 , CH3OH, H2O v NaH, MOMCl, DMF vi LiOH, CH3OH, THF, H2O vii 1,3-propanediol-PMB, DMAP, EDCI-HCl, CH2Cl2 viii DDQ, Sorenson’s buffer, CH2Cl2 
ix DMAP, EDCI-HCl, CH2Cl2 x THF, IPA/HCl xi CuCl2 , n-BuNH2, CH3OH xii LiOH, CH3OH, THF, H2O. 







EA 18.1 ± 3.06 4.05 ± 2.18 < 1%
1 70.2 103 ± 8.2 103 63.96 ± 4.31 < 1%
2 74.2 103 ± 7.7 103 26.84± 1.81 < 1%
3 585 ± 75 9.30 ± 3.03 < 1%
4 461 ± 224 56.38 ± 2.15 < 1%
5 3.72 103 ± 0.79 103 34.94 ± 5.97 < 1%
6 Liq. 54.33 ± 10.10 < 1%
7 646± 153 7.61 < 1%
8 Liq. 12.1 < 1%
9 Liq. 8.17 ± 1.80 < 1%
10 9.30 ± 0.15 1.90 ± 0.90 < 1%
11 / 1.75 ± 0.94 < 1%
Artemisinin : 0.1 to 7.8 10-4 µg/mL; 11 : 100 to 0.78 µg/mL; 
in 96-wells plate (8 two-folds dilutions).
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Total synthesis approach led to several promising compounds. Indeed, considering key properties, all
intermediates showed a non-toxic profile against red blood cells with a low to great inhibitory effect on
Plasmodium falciparum (3D7). A low IC50 value seems to be linked to a dimer-like structure i.e. two gallic
moieties with a short linker. In addition, most compounds exhibited a better water solubility than EA.
However one of the most active molecules was also found poorly soluble. The C-C bond between the 2
aromatic rings has now to be achieved and evaluated to follow evolution of these properties. Moreover,
cytotoxicity against human healthy cells will be performed to determine selectivity of our intermediates.
Figure 4: Bioassays
P. falciparum (3D7)
